Summary & Overview
HCPCS J0565: Injection, bezlotoxumab, 10 mg
HCPCS Level II code J0565 denotes the injection of bezlotoxumab, 10 mg, a monoclonal antibody used to reduce the risk of recurrent Clostridioides difficile infection. Nationally, this code matters because it captures billing for a targeted biologic therapy that may reduce recurrence and influence inpatient readmissions, post-acute utilization, and specialty pharmacy and infusion workflows. Payers commonly involved in coverage for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical context for use of bezlotoxumab, the typical sites of service where J0565 is billed, and which payers are commonly responsible for coverage. The publication provides benchmarks for utilization and reimbursement patterns, summarizes relevant policy and coverage considerations affecting access, and outlines billing and coding considerations tied to administration of an injectable biologic. The material is presented for a national audience and is intended to support billing professionals, clinicians, and policy analysts in understanding how J0565 is used and reimbursed across major payers. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0565 represents an injection of bezlotoxumab, 10 mg. This code denotes administration of a monoclonal antibody therapy indicated for preventing recurrence of Clostridioides difficile infection in high-risk patients. The service type is injectable biologic therapy, typically delivered as an infusion or intravenous injection in outpatient infusion centers, hospital outpatient departments, or physician offices depending on site capabilities and clinical setting.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult recently hospitalized for recurrent Clostridioides difficile infection (CDI) who is at high risk for recurrence due to advanced age, immunocompromise, severe CDI episode, or multiple prior CDI episodes. After completing standard-of-care antibiotic therapy (for example, oral vancomycin or fidaxomicin) and at the time of hospital discharge or during an outpatient infusion visit, the patient receives a single intravenous dose of bezlotoxumab (J0565, 10 mg per unit) administered by an infusion nurse in an outpatient infusion center, hospital outpatient department, or during a transitional care visit. The clinical workflow includes verification of indication and prior authorization if required, medication preparation by pharmacy, baseline vital signs and review of infusion history, administration over the recommended infusion time with monitoring for infusion-related reactions, documentation of lot number and units administered, and billing using the HCPCS Level II code J0565 with applicable modifier(s) to reflect payer-specific circumstances (for example, professional component, service termination, or drug wastage). Typical sites of service include outpatient infusion centers, hospital outpatient departments, and ambulatory clinics equipped for IV biologic administration. Patient consent and education about expected benefits (reduced risk of CDI recurrence) and potential adverse events (infusion reactions, heart failure exacerbation in susceptible patients) are documented in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|